Correction: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies

Ítems similars

• Bimekizumab Efficacy and Safety in Patients with Psoriatic Arthritis with Substantial Skin and Nail Psoriasis to 1 Year
  per: Diamant Thaçi, et al.
  Publicat: (2025-12-01)
• Comparative effectiveness of cycling versus swapping to IL-17 inhibitors after first TNF inhibitor failure in Psoriatic Arthritis: A real-world multicenter study
  per: Alarico Ariani, et al.
  Publicat: (2025-11-01)
• Matching-Adjusted Indirect Comparison of the 52-Week Efficacy of Bimekizumab Versus Secukinumab and Ixekizumab for the Treatment of Radiographic Axial Spondyloarthritis
  per: Walter P. Maksymowych, et al.
  Publicat: (2024-06-01)
• Predictors of response to bDMARDs and tsDMARDs in psoriatic arthritis: a pilot study on the role of musculoskeletal ultrasound
  per: Giacomo Cozzi, et al.
  Publicat: (2024-12-01)
• Secukinumab Persistence in Patients with Psoriatic Arthritis: An Adalimumab-Matched Retrospective Cohort Database Study (FLYWAY)
  per: Hideto Kameda, et al.
  Publicat: (2025-03-01)